AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16216977
Drug: Blood pressure-lowering
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure-lowering drugs (thiazides, β-blockers, ACE inhibitors, angiotensin II receptor antagonists)
Trial: 16216977
Drug: Blood pressure-lowering
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure-lowering drugs (all classes)
Trial: 11268707
Drug: Eflornithine HCl
RxNorm normalized name: eflornithine HCl
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eflornithine HCl 13.9% cream
Trial: 9834591
Drug: Continuous TIVA
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous TIVA with propofol, ketamine, and vecuronium in combination with butorphanol (PKBt)
Trial: 9834591
Drug: Continuous TIVA
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous TIVA with propofol, ketamine, and vecuronium in combination with buprenorphine (PKBp)
Trial: 2689472
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac tromethamine (10, 30, or 90 mg)
Trial: 2689472
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac tromethamine (combined doses)
Trial: 4603994
Drug: Intradermal cholera
RxNorm normalized name: VIBRIO CHOLERAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal cholera vaccine
Trial: 4603994
Drug: Subcutaneous cholera
RxNorm normalized name: VIBRIO CHOLERAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous cholera vaccine
Trial: 448844
Drug: Cefazolin sodium,
RxNorm normalized name: CeFAZolin Sodium, 1 g/10 mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin sodium, 500 mg intramuscularly twice daily
Trial: 448844
Drug: Penicillin G
RxNorm normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin G procaine, 600,000 units intramuscularly twice daily
Trial: 30654479
Drug: Placebo dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dietary supplement (fruit juice)
Trial: 25397864
Drug: Active laser
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active laser treatment (NIR light therapy) with a cumulative dose of 360 J
Trial: 24952882
Drug: Ultra Corega
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra Corega cream tasteless
Trial: 21975275
Drug: Tiotropium plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium plus FSC (250/50 μg twice daily)
Trial: 21975275
Drug: Tiotropium plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium plus FSC (250/50 μg twice daily) in GOLD stage II patients
Trial: 11313504
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol using metered dose inhaler via commercial spacer device (Group 1)
Trial: 11313504
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol using metered dose inhaler via improvised spacer device (Group II)
Trial: 9419773
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg every 4 hours for 48 hours postpartum)
Trial: 9419773
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (intravenous magnesium sulfate 2 g/hour)
Trial: 2845461
Drug: Theophylline infusion
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline infusion (mean = 14.0 micrograms/ml) in normal saline (308 mEq)
Trial: 2845461
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate infusion (350 mEq in normal saline)
Trial: 413639
Drug: Serogroup A
RxNorm normalized name: Meningococcus serogroup A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serogroup A meningococcal polysaccharide vaccine
Trial: 26242220
Drug: Olaparib 300
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300 mg (two 150 mg tablets) administered in fed state
Trial: 26242220
Drug: Olaparib 300
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300 mg (two 150 mg tablets) administered in fasted state
Trial: 16769267
Drug: Dai‐kenchu‐to (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dai‐kenchu‐to (15 g/d)
Trial: 14732896
Drug: Antituberculous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antituberculous treatment (Isoniazid, Rifampicin, Pyrazinamid, and Streptomycin) alone
Trial: 14732896
Drug: Antituberculous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antituberculous treatment plus additional pleural tapping for four weeks
Trial: 14732896
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (0.75 mg/kg body weight) tapered over four weeks (for both groups in phase II)
Trial: 10916329
Drug: Xylitol chewing
RxNorm normalized name: xylitol Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol chewing gum (n = 51), chewed three times daily for a minimum of five minutes each time for three months
Trial: 8645022
Drug: 1/2 FAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/2 FAM (5-FU 200 mg/m2/day IV, ADM 15 mg/m2/day IV, MMC 5 mg/m2/day IV)
Trial: 8645022
Drug: Control (palliative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (palliative treatment alone)
Trial: 3931363
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg glycerol trinitrate
Trial: 3931363
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg glycerol trinitrate after aortocoronary venous bypass
Trial: 28616088
Drug: Novafen administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novafen administration before periodontal surgery
Trial: 24969635
Drug: Midodrine (7.5-22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine (7.5-22.5 mg max) followed by penile vibratory stimulation (PVS)
Trial: 23936895
Drug: MSN (morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSN (morphine sulfate and naltrexone hydrochloride extended‐release)
Trial: 23936895
Drug: MS (controlled‐release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MS (controlled‐release morphine sulfate)
Trial: 20484613
Drug: Exenatide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (10 µg) administered at -60 minutes, -30 minutes, or -15 minutes
Trial: 20484613
Drug: Exenatide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (10 µg)
Trial: 20484613
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered at -30 minutes
Trial: 7018305
Drug: Lithium therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium therapy for 3 months
Trial: 7018305
Drug: Lithium therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium therapy for 3 months in depressed patients
Trial: 28436305
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no intra-arterial treatment)
Trial: 9641433
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac PLO (2% diclofenac)
Trial: 9215651
Drug: SEDDS formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEDDS formulation (1125 mg twice daily)
Trial: 9215651
Drug: Elixir (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elixir (750 mg three times daily)
Trial: 9215651
Drug: SEDDS formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEDDS formulation (750 mg three times daily)
Trial: 9215651
Drug: Twice-daily administration
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily administration
Trial: 6276278
Drug: New, specially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New, specially prepared swelling substances administered at the recommended doses
Trial: 27983733
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg caffeine drink
Trial: 18289194
Drug: Empirical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical treatment with esomeprazole 40 mg once daily for 4 weeks
Trial: 18289194
Drug: Endoscopy-oriented treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopy-oriented treatment (esomeprazole 40 mg od for reflux esophagitis, esomeprazole 20 mg od for no esophagitis) for 4 weeks
Trial: 18289194
Drug: Empirical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical treatment with esomeprazole 20 mg od maintenance treatment after 4 weeks
Trial: 18289194
Drug: Endoscopy-oriented treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopy-oriented treatment with esomeprazole 20 mg od maintenance treatment after 4 weeks
Trial: 18289194
Drug: Empirical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical treatment with esomeprazole
Trial: 18289194
Drug: Endoscopy-oriented treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopy-oriented treatment
Trial: 17052416
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg in 2mls)
Trial: 14983991
Drug: Nurse-administered protocol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-administered protocol (NP)
Trial: 10851773
Drug: Gentian violet
RxNorm normalized name: Gentian Violet
DrugBank: Gentian violet cation (DB00406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gentian violet topical application
Trial: 1905472
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein diet of high biological value (20-30 g/day) and high calorie content (3000 kcal/day) for 18 to 28 months
Trial: 1905472
Drug: Unrestricted protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unrestricted protein intake (40-60 g/day)
Trial: 6140023
Drug: Fazadinium 0.75,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fazadinium 0.75, 1.0, 1.25 mg kg‐1
Trial: 24714767
Drug: Aromatic white
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatic white spirits (aWS) at 100 mg/m(3)
Trial: 24714767
Drug: Aromatic white
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatic white spirits (aWS) at 300 mg/m(3)
Trial: 24714767
Drug: Dearomatized white
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dearomatized white spirits (daWS) at 100 mg/m(3)
Trial: 24714767
Drug: Dearomatized white
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dearomatized white spirits (daWS) at 300 mg/m(3)
Trial: 19062091
Drug: High-dose imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose imatinib (600-800 mg daily)
Trial: 19062091
Drug: Lower-dose (intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose (intermittent or pulsed) maintenance therapy
Trial: 17932364
Drug: Low-fat/low-glycemic load
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat/low-glycemic load diet (<20% energy from fat and total daily glycemic load <100)
Trial: 17932364
Drug: Standard American
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard American diet (approximately 35% energy from fat and total daily glycemic load >200)
Trial: 15534356
Drug: Cytarabine and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytarabine and escalated doses of daunorubicin and etoposide +/- PSC-833 (ADE/ADEP)
Trial: 15534356
Drug: One cycle
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One cycle of high-dose cytarabine (HDAC) followed by etoposide/cyclophosphamide and mitoxantrone/diaziquone (group I)
Trial: 15534356
Drug: Four intermediate-dose
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four intermediate-dose cytarabine (IDAC) or HDAC cycles (group III)
Trial: 11965510
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A plus iron supplementation (4800 RE vitamin A, 120 mg iron, and 500 microg folic acid)
Trial: 11965510
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (120 mg iron and 500 microg folic acid)
Trial: 9808874
Drug: Ethylephrine 75
RxNorm normalized name: Methylephedrine, (+/-)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethylephrine 75 mg/die
Trial: 9808874
Drug: Propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 80 mg/die
Trial: 2674593
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg.kg‐1) administered 60 min prior to exercise
Trial: 8653101
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg.kg‐1)
Trial: 807952
Drug: Intravenous methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous methotrexate followed by radical irradiation
Trial: 25402222
Drug: Work-related cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Work-related cognitive-behavioral treatment (W-CBT)
Trial: 25402222
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment as usual (CBT-AU)
Trial: 19386609
Drug: Terlipressin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin infusion alone for 5 days
Trial: 19386609
Drug: Banding ligation
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Banding ligation plus terlipressin infusion for 2 days
Trial: 16878187
Drug: Metoclopramide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (2 mg/kg) plus dimenhydrinate (5 mg/kg)
Trial: 11736727
Drug: 7-day rabeprazole-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day rabeprazole-based therapy (10 mg rabeprazole, 1000 mg amoxicillin, 500 mg clarithromycin, all twice daily)
Trial: 11736727
Drug: 3-day rabeprazole-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day rabeprazole-based therapy (20 mg rabeprazole, 1000 mg amoxicillin, 500 mg clarithromycin, all twice daily)
Trial: 11736727
Drug: 7-day omeprazole-based
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7-day omeprazole-based therapy (20 mg omeprazole, 1000 mg amoxicillin, 500 mg clarithromycin, all twice daily)
Trial: 8214728
Drug: Epidural butorphanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural butorphanol (BU) 3 mg
Trial: 8214728
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (MS)
Trial: 8214728
Drug: Epidural nalbuphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural nalbuphine (NB) 10 mg
Trial: 8214728
Drug: Oral naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral naltrexone (NX) 6 mg
Trial: 29716655
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg once daily for the first 6 weeks, then 10 mg once daily for the next 6 weeks)
Trial: 24403544
Drug: No Hib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Hib conjugate vaccine booster
Trial: 18540741
Drug: 1-session exposure-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-session exposure-based treatment plus inactive pill with sedating herb description
Trial: 18540741
Drug: 1-session exposure-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-session exposure-based treatment plus inactive pill with stimulating herb description
Trial: 18540741
Drug: 1-session exposure-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-session exposure-based treatment plus inactive pill with placebo description
Trial: 18540741
Drug: 1-session exposure-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-session exposure-based treatment
Trial: 10082241
Drug: CCK4 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCK4 (25 microg, i.v. injection)
Trial: 8851038
Drug: Cetirizine 10
RxNorm normalized name: cetirizine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 10 mg once a day
Trial: 2261015
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide 0.1% cream with Duoderm dressing
Trial: 2261015
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide 0.1% cream with Actiderm dressing
Trial: 366723
Drug: Diflunisal 250
RxNorm normalized name: diflunisal 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal 250 mg to 375 mg twice daily
Trial: 366723
Drug: Aspirin 500
RxNorm normalized name: aspirin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 500 mg to 750 mg four times daily
Trial: 31260678
Drug: 37.5 mg
RxNorm normalized name: pemoline 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37.5 mg prednisolone/d for 5 days
Trial: 23485142
Drug: Buckwheat crackers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buckwheat crackers (daily for 1 week)
Trial: 1540093
Drug: Norfloxacin, 500-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin, 500-mg suspension every 8 hours, and nystatin, 1 million units every 6 hours
Trial: 1540093
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo solutions administered through a nasogastric tube
Trial: 25761488
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m² intravenously every 3 weeks
Trial: 25761488
Drug: Gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250 mg/day orally
Trial: 21850515
Drug: Choice over
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choice over treatment options (two pain-relieving treatments, same inert ointment mixture)
Trial: 21850515
Drug: No choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No choice over treatment options (two pain-relieving treatments, same inert ointment mixture)
Trial: 21850515
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (no treatment expectation)
Trial: 10930905
Drug: OAC (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC (omeprazole 20 mg, amoxycillin 1500 mg, clarithromycin 600 mg for 7 days)
Trial: 10930905
Drug: OAC +
RxNorm normalized name: Oral Anticoagulant Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC + CET (OAC plus cetraxate 600 mg for 7 days)
Trial: 9283508
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (treated in the usual manner)
Trial: 8436150
Drug: isradipine SRO
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: isradipine SRO 5 mg once daily
Trial: 26817533
Drug: levodopa‐carbidopa intestinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levodopa‐carbidopa intestinal gel
Trial: 26817533
Drug: oral levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral levodopa treatment
Trial: 25359307
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine (Yi‐Qi‐Jian‐Pi and Qu‐Tan‐Hua‐Zhuo granule) plus conventional medicine
Trial: 25359307
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine (Yi‐Qi‐Jian‐Pi and Qu‐Tan‐Hua‐Yu granule) plus conventional medicine
Trial: 25359307
Drug: Placebo medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medicine plus conventional medicine
Trial: 25359307
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (including both treatment and control)
Trial: 22897374
Drug: 40 %
RxNorm normalized name: oxygen 40 %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 % O2 + 60 % N2O, 1‐2 % sevoflurane and 50 µg fentanyl + 2 mg vecuronium every 45 minutes
Trial: 20708634
Drug: Carriers with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carriers with class S allele (L/S or S/S genotypes)